Cash Flow Statement

Currency: USD

	Dec-2020	Mar-2021	Jun-2021	Sep-2021	Dec-2021	Mar-2022	Jun-2022	Sep-2022	Dec-2022	Mar-2023	Jun-2023	Sep-2023	Dec-2023	Mar-2024
Operating Cash Flow
Net Income	(7)	(8)	(11)	(21)	(33)	(44)	(54)	(60)	(63)	(67)	(68)	(63)	(58)	(56)
Depreciation & Amortization	0	0	0	0	0	0	0	1	1	1	2	2	2	2
Stock-Based Compensation	0	0	1	4	7	11	14	16	17	19	20	20	20	0
Other Non-Cash Items	0	0	1	4	7	11	14	15	15	15	14	13	12	12
Change in Working Capital	2	9	7	9	9	(1)	7	3	4	6	(2)	(5)	(7)	(10)
Cash from Operating Activities	(4) N/A	2 N/A	(3) N/A	(8) -143%	(17) -109%	(34) -101%	(34) +0%	(41) -22%	(43) -3%	(45) -6%	(54) -20%	(53) +3%	(51) +4%	(52) -2%
Investing Cash Flow
Capital Expenditures	0	(0)	(0)	(0)	(1)	(2)	(3)	(6)	(6)	(6)	(5)	(3)	(2)	(2)
Other Items	0	0	(143)	(348)	(339)	(307)	(155)	73	65	24	33	(51)	(39)	(144)
Cash from Investing Activities	0 N/A	(0) N/A	(143) -95 067%	(348) -144%	(341) +2%	(310) +9%	(158) +49%	67 N/A	58 -13%	18 -68%	27 +48%	(54) N/A	(41) +24%	(146) -255%
Financing Cash Flow
Net Issuance of Common Stock	9	67	187	187	182	125	0	0	1	2	2	59	60	380
Net Issuance of Debt	3	1	0	0	0	0	0	0	0	0	0	0	0	0
Other	0	(0)	205	204	204	204	(1)	0	0	0	0	0	0	0
Cash from Financing Activities	12 N/A	68 +487%	392 +480%	391 0%	387 -1%	329 -15%	(0) N/A	0 N/A	1 +6%	2 +316%	2 +11%	59 +2 461%	60 +1%	380 +538%
Change in Cash
Net Change in Cash	7 N/A	69 +872%	246 +253%	34 -86%	29 -17%	(15) N/A	(192) -1 197%	26 N/A	16 -39%	(25) N/A	(25) +0%	(48) -93%	(32) +32%	182 N/A
Free Cash Flow
Free Cash Flow	(4) N/A	2 N/A	(4) N/A	(8) -136%	(18) -119%	(36) -97%	(37) -2%	(47) -27%	(49) -5%	(51) -3%	(60) -17%	(56) +6%	(52) +6%	(53) -2%

Janux Therapeutics Inc
NASDAQ:JANX